Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02365818 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade NMIBC After BCG Failure
A Phase 2 study, sponsored by CG Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
NCT02365818: Completed Phase 2 study, sponsored by CG Oncology.
NCT02365818 is a Phase 2 study that has completed, run by CG Oncology. The registered enrollment target is 66 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02365818, a Phase 2 study, has completed, sponsored by CG Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
Study Summary
To study the safety and efficacy of CG0070, an oncolytic virus expression GM-CSF in high grade non muscle invasive bladder cancer patients who failed BCG therapy and refused cystectomy.
Primary Outcome
Defined as the proportion of patients who experience a durable complete response lasting 12 months or longer from the initial confirmed complete response date (first CR assessment to be at least 6 months after the first intravesical intervention) and at least 18 months from the date of the first intravesical intervention
Interventions
- BIOLOGICAL CG0070
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2015-06-02 |
| Est. Completion | 2019-02 |
| Phase | Phase 2 |
What the finished NCT02365818 record still lists
NCT02365818 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 66 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% lower).
The record links to 0 conditions, and to 1 intervention - of which CG0070 is the first listed.
NCT02365818 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02365818 about?
NCT02365818 is a clinical study titled "Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade NMIBC After BCG Failure". To study the safety and efficacy of CG0070, an oncolytic virus expression GM-CSF in high grade non muscle invasive bladder cancer patients who failed BCG therapy and refused cystectomy.
What is the current status of trial NCT02365818?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2015-06-02. Estimated completion is 2019-02.
What interventions are being tested in trial NCT02365818?
The interventions under investigation include: CG0070 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02365818?
This trial is sponsored by CG Oncology, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02365818's enrollment target sits among peer trials
66 975th of 2000 higher than 1,014 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02584244 · 66 participants · Phase 1
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- NCT03067051 · 66 participants · Phase 1
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
- NCT03754725 · 66 participants · Phase 1
Ferritin and Iron Burden in SAH sIRB
- NCT03875378 · 66 participants · Phase 2
Transdermal Estrogen in Women With Anorexia Nervosa
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI